Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490): Appraisal consultation document

DRAFT guidance does not recommend use within its marketing authorisation as the cost-effectiveness estimates are highly uncertain, but they are likely to be at the higher end of what NICE considers an acceptable use of NHS resources, and could exceed the maximum.

Source:

National Institute for Health and Care Excellence